Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
vaccine
|
| gptkbp:administeredBy |
intramuscular injection
|
| gptkbp:age |
adults
children (5-12 years) |
| gptkbp:approvedBy |
gptkb:India
|
| gptkbp:boostersApproved |
yes
|
| gptkbp:contains |
recombinant RBD protein
CpG 1018 adjuvant aluminum hydroxide adjuvant |
| gptkbp:developedBy |
gptkb:Biological_E._Limited
gptkb:Baylor_College_of_Medicine |
| gptkbp:emergencyUseAuthorizationDate |
2021-12-28
|
| gptkbp:form |
two doses
|
| https://www.w3.org/2000/01/rdf-schema#label |
Corbevax
|
| gptkbp:intellectualPropertyStatus |
patent-free
|
| gptkbp:intervalBetweenDoses |
28 days
|
| gptkbp:pricePerDose |
~250 INR
|
| gptkbp:publiclyFunded |
yes
|
| gptkbp:storage |
2-8°C
|
| gptkbp:target |
gptkb:COVID-19
|
| gptkbp:technologyOrigin |
Texas Children's Hospital Center for Vaccine Development
|
| gptkbp:type |
protein subunit vaccine
|
| gptkbp:usedIn |
gptkb:Botswana
gptkb:India gptkb:Philippines |
| gptkbp:WHOStatus |
not yet WHO listed
|
| gptkbp:bfsParent |
gptkb:Biological_E._Limited
|
| gptkbp:bfsLayer |
7
|